


 Substitute Form PTO-1449
(Modified)

 U.S. Department of Commerce
Patent and Trademark Office

 Attorney's Docket No.
10274-034001

 Application No.
09/805,840

**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

 Applicant
Mundy et al.

 Filing Date
March 13, 2001

 Group Art Unit
1644

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	No
	AD							
	AE							
	AF							
	AG							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
MH	AH	Barlogie et al., "Extended survival in advanced and refractory multiple", July 15, 2001, Blood, vol.98(2):492 (abstract)
mH	AI	Berenson et al., "Long-Term Pamidronate Treatment of Advanced Multiple Myeloma", Feb. 1998, J. Clin. Oncology, vol. 16 (2):593 (abstract)
mH	AJ	Dallas et al., "Ibandronate Reduces Osteolytic Lesions but not Tumor Burden", March 1, 1998, Blood, vol. 93(5):1697 (abstract)
mH	AK	Damiano et al., "Integrin-Mediated Drug Resistance in Multiple Myeloma", 2000, Leukemia and Lymphoma, vol. 38 (1-2):71-81
mH	AL	Damiano et al., "Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins", March 1, 1999, Blood, vol. 93(5):1658-1667
mH	AM	Mittelman et al., "Erythropoietin induces tumor regression and antitumor", Aug. 24, 2001, PNAS, vol. 98(9):5181 (abstract)
mH	AN	Mundy et al., "Stromal cells regulate survival of B-lineage leukemic cells", Sept. 1, 2000, Blood, vol. 96 (5):1926-1932
mH	AO	Tinhofer et al., "Expression of functional interleukin-15 receptor and autocrine production", Jan. 15, 2000, Blood, vol. 95 (2): 610 (abstract)

Examiner Signature

Maher Haddad

Date Considered

4/7/04

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.